BONEH BBS-Bioactive Bone Substitutes Oyj

BBS to present at Småbolagsdagen in Stockholm

BBS to present at Småbolagsdagen in Stockholm

BBS – Bioactive Bone Substitutes, an innovator in orthobiologics, today announced that the company’s Chief Commercial Officer (CCO) Paul Watkins will present the company at Småbolagsdagen in Stockholm on June 3, 2019.

Småbolagsdagen is a capital market’s day arranged by Aktiespararna that takes place on Monday June 3, 2019, at Sheraton Hotel in Stockholm, Sweden. BBS – Bioactive Bone Substitutes CCO Paul Watkins will present the company in brief at 10:40 am, followed by a short Q&A session. The company’s CEO, Pekka Jalovaara, will also be attending the event.

More information about the event and forms for registration can be found on Aktiespararna’s website: /smabolagsdagen.

Contact

Pekka Jalovaara, CEO

Phone: +358 505 52 92 75

E-mail:

Paul Watkins, CCO

Phone: +358 404 856 034

E-mail:

About BBS – Bioactive Bone Substitutes

BBS-Bioactive Bone Substitutes Plc is a leading orthobiologic biotech company with origins in Finland. The company’s technology, Artebone®, is a next generation bone substitute that targets treatment of bone defects and healing problems in extremities such as hands and ankles, scapula and pelvis. Its superior properties stem from the natural growth factors extracted from reindeer bone combined with scaffold-providing TCP (tricalciumphosphate) granules and has the potential of transforming orthopedic surgery. The first product, Artebone® ready-to-use paste, is complete and the application process for the CE-marking enabling commercialization is in progress. BBS’ Certified Adviser at Nasdaq First North Stockholm and Helsinki is Stockholm Certified Advisers AB, , . More information: .

EN
29/05/2019

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on BBS-Bioactive Bone Substitutes Oyj

 PRESS RELEASE

Changes in BBS-Bioactive Bone Substitutes Plc’s Management Team

Changes in BBS-Bioactive Bone Substitutes Plc’s Management Team BBS-Bioactive Bone Substitutes Plc, Company announcement, 6 March 2024 at 11:15 a.m. Changes in the BBS-Bioactive Bone Substitutes Plc’s Management Team Oy Jamerco Ltd. has terminated its service contract with BBS-Bioactive Bone Substitutes Ltd (“BBS”). As a result, Jari Kortesluoma’s position as the CFO and member of the management team will end. Kortesluoma will fulfill the responsibilities of CFO throughout the two-month notice period. BBS is currently in the process of searching for a new in-house CFO. The appoi...

 PRESS RELEASE

Muutos BBS-Bioactive Bone Substitutes Oyj:n johtoryhmässä

Muutos BBS-Bioactive Bone Substitutes Oyj:n johtoryhmässä BBS-Bioactive Bone Substitutes Oyj, yhtiötiedote, 6.3.2024 klo 11:15 Muutos BBS-Bioactive Bone Substitues Oyj:n johtoryhmässä Oy JAMERCO Ltd. on tänään irtisanonut palvelusopimuksen BBS-Bioactive Bone Substitutes Oyj:n (BBS) kanssa, minkä seurauksena Jari Kortesluoman tehtävä BBS:n talousjohtajana ja johtoryhmän jäsenenä päättyy. Jari Kortesluoma jatkaa BBS:n talousjohtajan tehtävien hoitamista kahden kuukauden irtisanomisajan puitteissa. BBS hakee uutta työsuhteista talouspäällikköä ja nimityksestä tiedotetaa...

 PRESS RELEASE

BBS-Bioactive Bone Substitutes Plc: Financial Statements Bulletin 2023...

BBS-Bioactive Bone Substitutes Plc: Financial Statements Bulletin 2023: Preparations for commercial phase initiated (unaudited) BBS-Bioactive Bone Substitutes Plc, Financial Statements Bulletin 2023, 26 February 2024 at 5.45 p.m. (EET) This is a summary of BBS-Bioactive Bone Substitutes Plc’s Financial Statements Bulletin for January–December 2023. The entire report is attached to this Company Announcement as a pdf file. The report is also available on BBS-Bioactive Bone Substitutes Plc’s website at . Preparations for commercial phase initiated JULY-DECEMBER HIGHLIGHTS In the secon...

 PRESS RELEASE

BBS-Bioactive Bone Substitutes Oyj: Tilinpäätöstiedote 2023: Kaupallis...

BBS-Bioactive Bone Substitutes Oyj: Tilinpäätöstiedote 2023: Kaupallisen vaiheen valmistelut alkaneet (tilintarkastamaton) BBS-Bioactive Bone Substitutes Oyj, Tilinpäätöstiedote, 26.2.2024 klo 17.45 Tämä tiedote on tiivistelmä BBS-Bioactive Bone Substitutes Oyj:n tilinpäätöstiedotteesta tammi–joulukuu 2023. Koko raportti on tämän yhtiötiedotteen liitteenä pdf-tiedostona. Raportti on saatavilla myös BBS-Bioactive Bone Substitutes Oyj:n verkkosivuilla osoitteessa. Kaupallisen vaiheen valmistelut alkaneet HEINÄ-JOULUKUU Vuoden 2023 toisella puoliskolla BBS eteni merkittävästi ensimmäisen ...

 PRESS RELEASE

Inside information - BBS-Bioactive Bone Substitutes Plc: Drawdown of a...

Inside information - BBS-Bioactive Bone Substitutes Plc: Drawdown of an advance pursuant to financing arrangement between BBS-Bioactive Bone Substitutes Plc and RiverFort to strengthen the working capital position BBS-Bioactive Bone Substitutes Plc, Company announcement, inside information, 21 February 2024 at 10:30 am EET Drawdown of an advance pursuant to financing arrangement between BBS-Bioactive Bone Substitutes Plc and RiverFort to strengthen the working capital position BBS-Bioactive Bone Substitutes Plc's (“BBS”, “the Company”) has signed the drawdown of the advance of EUR 500...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch